Briefly, 29 missense CDKN2A variants affecting p16INK4A that were previously reported in patients with familial pancreatic cancer, PDAC, or reported in ClinVar as VUSs were selected (Chaffee et al., 2018; Hu et al., 2018; McWilliams et al., 2018; Roberts et al., 2016; Shindo et al., 2017; Zhen et al., 2015). This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.